Ascletis granted us a non-exclusive, sublicensable, royalty-free license under certain intellectual property of Ascletis to develop, manufacture, and commercialize denifanstat and products containing…
The Company granted Ascletis and its affiliates an exclusive, royalty-bearing sublicensable right and license under the Company’s intellectual property to develop, manufacture, commercialize and othe…
We are eligible to receive tiered royalty payments from Ascletis ranging from high single digit to mid-teen percentages on annual net sales of denifanstat and other products containing licensed compo…
TAPI granted the Company a global, exclusive license to certain intellectual property rights covering innovative forms of TAPI’s resmetirom active pharmaceutical ingredient (API) for Sagimet’s techni…
Sagimet Biosciences Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SGMT-DEBT
Debt stack $39,000
90%
Market cache reports total debt of $39,000.
SGMT-DEBT-12509
Warrants outstanding: -4000
90%
xbrl warrant detail from xbrl 2023-12-31.
Sagimet Biosciences Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Sagimet Biosciences Inc..
Sagimet Biosciences Inc. Ownership
Holder
Name
Confidence
Evidence
SGMT-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 87 tracked holders.
Sagimet Biosciences Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
